Wedmont Private Capital Invests $127,000 in Sotera Health (NASDAQ:SHC)

Wedmont Private Capital purchased a new stake in Sotera Health (NASDAQ:SHC) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,251 shares of the company’s stock, valued at approximately $127,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in shares of Sotera Health by 27.6% in the 1st quarter. Principal Financial Group Inc. now owns 468,500 shares of the company’s stock worth $5,627,000 after acquiring an additional 101,430 shares in the last quarter. Findell Capital Management LLC acquired a new stake in shares of Sotera Health during the 4th quarter worth approximately $8,425,000. P2 Capital Partners LLC lifted its holdings in shares of Sotera Health by 27.0% in the 4th quarter. P2 Capital Partners LLC now owns 2,350,000 shares of the company’s stock worth $39,598,000 after purchasing an additional 500,000 shares during the last quarter. Tyro Capital Management LLC acquired a new position in Sotera Health during the 4th quarter valued at approximately $15,761,000. Finally, Dimensional Fund Advisors LP grew its stake in Sotera Health by 22.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,717 shares of the company’s stock worth $33,581,000 after buying an additional 363,628 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Price Performance

Shares of NASDAQ:SHC opened at $14.93 on Wednesday. The company has a market capitalization of $4.23 billion, a PE ratio of 78.58 and a beta of 2.06. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. The stock has a fifty day moving average of $12.66 and a 200-day moving average of $12.82. Sotera Health has a one year low of $10.71 and a one year high of $17.44.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The company had revenue of $277.00 million for the quarter, compared to analyst estimates of $266.45 million. During the same period in the previous year, the firm earned $0.19 earnings per share. Sotera Health’s revenue for the quarter was up 8.6% compared to the same quarter last year. As a group, equities analysts anticipate that Sotera Health will post 0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SHC has been the topic of a number of recent research reports. Barclays raised their target price on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research report on Tuesday, August 6th. Finally, Piper Sandler began coverage on Sotera Health in a research note on Tuesday, May 21st. They set a “neutral” rating and a $13.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.70.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.